You are here
Research and progress in antiemetics: newer results influencing practical aspects of cancer care
Presentation by Dr. Richard Gralla at the TAO Congress on 19/20 November 2015
Despite marked progress in effective antiemetic prophylaxis, new antiemetic regimens are necessary, as many patients still experience emesis with chemotherapy, particularly during the delayed phase. Among the reasons for emetic failure are that patients are not always prescribed effective guidelines-based antiemetic regimens and that patients frequently do no adhere to delayed emesis regimens.
Dr. Richard Gralla presents new aspects of antiemetic treatment which can affect practice, i.e. new agents, new indications, updated guidelines and new evidence. He reviews the NK1 receptor antagonist agents aprepitant, fos-aprepitant, netupitant (NEPA) and rolapitant, presenting the results of several recent studies concerning these agents. He also discusses the potential of olanzapine in difficult settings, where it may be used as a fourth drug in addition to an antiemetic regimen, and the use of dexamethasone.
Dr. Gralla also stresses the importance of administering guideline-consistent antiemetic prophylaxis and presents an overview of the antiemetic recommendations from the evidence-based guidelines by NCCN, ASCO and MASCC/ESMO.
Dr. Richard Gralla, A. Einstein School of Medicine, New York, USA